2018年FIGO与本地晚期宫癌的体遗传分期:国际多中心队列研究,比较两个分类及其预后影响
Bruno Rezende1, Benjamin Wolf2,3, Vinicius Colman4
1Department of Gynecologic Oncology, Londrina Cancer Hospital, Lucilla Ballalai, 212-Jardim Petrópolis, Londrina 86015-520, Brazil.
Cancers
|February 27, 2026
概括
与FIGO 2018系统相比,本体遗传瘤分期系统为局部晚期宫癌提供了更高的预后准确性. 这种先进的分期方法改善了宫癌患者的生存结果的预测.
科学领域:
- 妇科瘤学 妇科瘤学
- 放射治疗瘤学 放射治疗瘤学
- 医疗成像医学成像
背景情况:
- 局部发达的宫癌需要准确的预后工具.
- 目前的分期系统,如FIGO 2018,在预测结果方面可能存在局限性.
- 本体遗传瘤分期系统是评估宫癌进展的新方法.
研究的目的:
- 为了比较本体遗传瘤分期系统与FIGO 2018宫癌分期系统的预后性能.
- 为了确定哪个分期系统更好地预测化学放射治疗患者的瘤结果.
主要方法:
- 一项多中心回顾性队列研究包括341名患有局部晚期宫癌的患者 (FIGO 2018阶段IIB-IVA).
- 患者接受了初级化疗或放射治疗.
- 对癌症特异性存活率,无复发存活率和整体存活率的预后准确度的比较,使用统计模型和像Harrell的C指数和AUC这样的指标.
主要成果:
- 在FIGO 2018系统上,本体遗传瘤分期系统表现出优越的预后性能.
- 卡普兰 - 梅尔曲线显示出明显的生存分离与本体遗传阶段,与FIGO 2018的重叠曲线不同.
- 多变量考克斯模型和统计比较证实了本体遗传模型的更好的区分能力和适应性,在子组内提供了显著的风险分层.
结论:
- 通过仅仅通过成像进行的本体遗传瘤分期优于FIGO 2018对局部晚期宫癌的分类.
- 这一发现支持使用本体遗传分期来改善预后评估和治疗规划.
更多相关视频
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
956
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
7.3K
相关概念视频
02:07Tumor Progression
7.6K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.6K
01:21Cancer Survival Analysis
805
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
805